8-K: DocGo Announces Record Fourth Quarter and Full-Year 2023 Results, Updates 2024 Guidance

DocGo reported record fourth-quarter and full-year 2023 results, with significant revenue growth and increased adjusted EBITDA, while also updating its 2024 revenue guidance to $720-$750 million and introducing adjusted EBITDA guidance of $80-$85 million.

Summary

• DocGo announced its financial results for the fourth quarter and full year of 2023, showing substantial growth in revenue and adjusted EBITDA.
• Fourth-quarter revenue reached $199.2 million, an 83% increase compared to $108.8 million in the same period of 2022.
• The company's gross margin for the fourth quarter was 33.5%, down from 39.0% in the prior year, due to start-up costs associated with rapid growth.
• Net income for the fourth quarter was $8.0 million, a 13% increase from $7.1 million in the fourth quarter of 2022.
• Adjusted EBITDA for the fourth quarter was $22.6 million, a 232% increase from $6.8 million in the fourth quarter of 2022.
• Full-year 2023 revenue increased by 42% to $624.2 million, compared to $440.5 million in 2022.
• The full-year gross margin was 31.3%, down from 35.1% in 2022, due to project start-up costs.
• Full-year net income decreased by 67% to $10.0 million, compared to $30.7 million in 2022, due to increased stock-based compensation and an income tax provision.
• Full-year adjusted EBITDA increased by 31% to $54.0 million, compared to $41.3 million in 2022.
• Mobile Health Services revenue for the full year was $442.8 million, a 36% increase, and Transportation Services revenue was $181.5 million, a 58% increase.
• The company held $72.2 million in cash and cash equivalents as of December 31, 2023, and received approximately $120 million in payments subsequent to year-end.
• DocGo has provided 2024 revenue guidance of $720-$750 million and adjusted EBITDA guidance of $80-$85 million.
• The company also expects full-year 2024 cash flow from operations to be $65-$75 million.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue and adjusted EBITDA growth, but the decrease in net income and gross margin, along with the risks mentioned, temper the overall sentiment.

Positives

• The company experienced significant revenue growth in both the fourth quarter and full year of 2023.
• Adjusted EBITDA saw substantial increases, indicating improved operational efficiency.
• DocGo is expanding its payer relationships and launching new government health programs.
• The company has secured a first payer partnership with a major insurance company that includes risk sharing.
• The company has a strong cash position and has bolstered its balance sheet with $120 million in payments received after year end.
• The company has paid down its line of credit in full.
• The company has announced a share repurchase program for up to $36 million.
• The company is seeing positive results from its Transitional Care Management program with LA Care.

Negatives

• Gross margins decreased year-over-year due to start-up costs associated with rapid growth.
• Full-year net income decreased significantly due to increased stock-based compensation and an income tax provision.
• Cash and cash equivalents decreased from $164.1 million at the end of 2022 to $72.2 million at the end of 2023.

Risks

• The company's future performance is subject to risks related to its ability to maintain contractual relationships, compete effectively, and manage growth.
• There are risks associated with government contracts and potential changes in government policies regarding immigration and asylum seekers.
• The company faces risks related to macroeconomic factors, including inflation, economic slowdown, and rising interest rates.
• The company's stock price is subject to volatility.
• There are risks associated with information technology system failures, cybersecurity incidents, and data privacy.
• The company's forward-looking statements are subject to substantial risks and uncertainties that could cause actual results to differ materially.

Future Outlook

DocGo expects full-year 2024 revenues to be between $720 and $750 million and adjusted EBITDA to be between $80 and $85 million. The company also anticipates cash flow from operations to be between $65 and $75 million. They expect some moderation in migrant-related revenues and a decrease in start-up costs associated with recent program launches.

Management Comments

• Lee Bienstock, CEO, expressed pride in the company's operational execution and expanding payer relationships.
• Norm Rosenberg, CFO, noted that they expect to see increased profitability due to moderating agency labor and overtime utilization rates.

Industry Context

DocGo's results reflect a growing trend in the healthcare industry towards mobile health services and remote patient monitoring. The company's expansion into new markets and partnerships with major insurance companies and hospital systems aligns with the industry's focus on value-based care and improving access to healthcare.

Comparison to Industry Standards

• While DocGo's revenue growth is impressive, the decrease in gross margin and net income compared to the previous year is a concern.
• Companies like American Well (AMWL) and Teladoc Health (TDOC) also operate in the telehealth space, but their financial performance and focus areas differ.
• DocGo's adjusted EBITDA growth is a positive sign, but it's important to compare this to other companies in the mobile health services sector.
• The company's focus on value-based care and partnerships with payers is similar to trends seen in other healthcare companies.
• The share repurchase program is a positive signal to investors, but its impact will depend on market conditions and the company's financial performance.

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue and adjusted EBITDA growth, as well as the share repurchase program.
• Employees may benefit from the company's growth and expansion.
• Customers will benefit from the company's expanded services and partnerships.
• Suppliers may see increased business opportunities with the company's growth.
• Creditors may view the company's financial performance positively.

Next Steps

• The company plans to commence a share repurchase program in early March.
• DocGo will continue to expand its payer relationships and launch new government health programs.
• The company will focus on expanding its Transitional Care Management program with LA Care.
• The company will continue to monitor and manage its agency labor and overtime utilization rates.

Key Dates

Keywords

Mobile Health Services, Transportation Services, Adjusted EBITDA, Revenue Growth, Healthcare, Telehealth, Patient Monitoring, Share Repurchase, Financial Results, Guidance